Emerald Advisers’s GeneDx Holdings WGS Stock Holding History

Emerald Advisers’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-91,818	Closed	-$7.06M	–	271
2024 Q4	$7.06M	Buy	+91,818	New	+$6.41M	0.27%	104

Other funds holding WGS

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Emerald Advisers's WGS Position: Q1 2025 in Review

Emerald Advisers sold out of GeneDx Holdings (WGS) in Q1 2025, closing a stake of 91,818 shares — an estimated $7.06M sold.

Emerald Advisers first reported a position in WGS in Q4 2024 and held it in 1 quarter. The position peaked at $7.06M in Q4 2024. 225 funds tracked by Wall St. Rank hold WGS as of Q1 2025.

Emerald Advisers reported no remaining GeneDx Holdings position as of Q1 2025 after selling out during the quarter.
Emerald Advisers sold 91,818 GeneDx Holdings shares in Q1 2025, an estimated $7.06M.
Emerald Advisers first reported a position in GeneDx Holdings in Q4 2024 and held it in 1 quarter.
Emerald Advisers's GeneDx Holdings position peaked at $7.06M in Q4 2024.
225 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2025.

Based on Emerald Advisers's 13F filing for Q1 2025, filed 1 May 2025.